Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension

What Was Tested

This controlled clinical trial paper looks at Methylene blue (non-peptide stack partner).

Plasma nitric oxide (NO) levels have been found to be high in haemodialysis (HD) patients, especially in those prone to hypotension in dialysis.

Who Took Part

The study group was 18 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults.

MB was given i.v. in 18 stable HD patients with hypotensive episodes during almost every dialysis, in 18 HD patients without hypotension during dialyses, and in five healthy controls.

How the Study Was Run

Systolic and diastolic blood pressures (BP) were measured at 10-min intervals during HD sessions with or without MB and on a non-dialysis day with MB.

What Was Measured

Plasma nitric oxide (NO) levels have been found to be high in haemodialysis (HD) patients, especially in those prone to hypotension in dialysis.

PubMed files the paper under topics including Blood Platelets, Blood Pressure, Diastole, Enzyme Inhibitors, Hypotension, Kidney Failure, Chronic and Methylene Blue.

What This Means in Plain Language

This is a controlled clinical trial of Methylene blue (non-peptide stack partner) in 18 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.